HAVCR2 and neoplasm: In the case for TIM-3, that is expressed on both DCs and T cells, expression of TIM-3 is associated with both the inhibition of antigen presentation on DCs and on exhaustion of T cells, and TIM3 antibody treatment reverses these phenotypes and improves tumor outcomes [131].